Erschienen in:
30.04.2021 | Hepatobiliary Tumors
Chemotherapy-Associated Liver Injuries: Unmet Needs and New Insights for Surgical Oncologists
verfasst von:
Luca Vigano, MD, PhD, Martina Sollini, MD, PhD, Francesca Ieva, PhD, Francesco Fiz, MD, Guido Torzilli, MD, PhD
Erschienen in:
Annals of Surgical Oncology
|
Ausgabe 8/2021
Einloggen, um Zugang zu erhalten
Excerpt
Chemotherapy-associated liver injuries (CALI) were the focus of several research studies some years ago when they were associated with modern treatments for colorectal metastases and operative outcomes of liver resection.
1,
2 An intensive, multidisciplinary commitment was designed to elucidate their pathogenesis, risk factors, clinical impact, diagnosis, and prevention. Then, long before reaching a full understanding, the interest in CALI rapidly decreased. The definition itself of CALI remains uncertain. While sinusoidal dilatation and nodular regenerative hyperplasia (NRH) are unequivocally associated with oxaliplatin-based chemotherapy regimens, this is not the case for steatohepatitis.
1,
3 For the latter, a major, if not exclusive, impact of metabolic disorders rather than of irinotecan has been outlined.
4,
5 …